1. Home
  2. PARK vs RLYB Comparison

PARK vs RLYB Comparison

Compare PARK & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

HOLD

Current Price

$21.18

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

N/A

Current Price

$16.84

Market Cap

86.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PARK
RLYB
Founded
1972
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.5M
86.6M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PARK
RLYB
Price
$21.18
$16.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.3K
20.6K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.16
6.16
Revenue
N/A
$858,000.00
Revenue This Year
$7.06
N/A
Revenue Next Year
$6.17
N/A
P/E Ratio
$132.50
$2.76
Revenue Growth
N/A
43.00
52 Week Low
$12.29
$0.48
52 Week High
$26.79
$17.57

Technical Indicators

Market Signals
Indicator
PARK
RLYB
Relative Strength Index (RSI) 55.94 54.07
Support Level $16.63 $15.68
Resistance Level $21.86 $17.34
Average True Range (ATR) 1.89 0.48
MACD 0.12 0.02
Stochastic Oscillator 38.58 49.33

Price Performance

Historical Comparison
PARK
RLYB

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: